Inventiva Announces Shareholders’ Meeting Vote Results

Inventiva, a clinical-stage biopharmaceutical company listed on Euronext Paris and Nasdaq, announced the results of its Combined Shareholders' General Meeting held on December 11, 2024. The meeting took place in Dijon, France, and was chaired by Frédéric Cren, CEO and co-founder of Inventiva. The majority of the proposed resolutions were adopted.

Only the 59th resolution was rejected after receiving a negative recommendation from the Board of Directors. This resolution aimed to grant the Board authority to increase share capital for a company savings plan. Shareholders approved the compensation policy for corporate officers as presented in the Board's report.

The meeting reached a quorum of 79.738%, with 81,408,142 votes cast for both ordinary and extraordinary resolutions. This outcome supports Inventiva’s ongoing strategic and operational directives.